- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00104962
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
Phase I Study of CC-5013 (Lenalidomide NSC# 703813) in Pediatric Patients With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome
Studienübersicht
Status
Bedingungen
- Nicht näher bezeichneter solider Tumor im Kindesalter, protokollspezifisch
- Myelodysplastische Syndrome im Kindesalter
- Zuvor behandelte myelodysplastische Syndrome
- Sekundäre myelodysplastische Syndrome
- de Novo Myelodysplastische Syndrome
- Refraktäre Anämie
- Refraktäre Anämie mit übermäßigen Blasten
- Refraktäre Zytopenie mit Multilineage-Dysplasie
- Refraktäre Anämie mit Ringsideroblasten
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose and recommended phase II dose of lenalidomide in pediatric patients with relapsed or refractory solid tumors.
II. Determine the toxic effects of this drug in these patients. III. Determine the pharmacokinetics of this drug in these patients.
SECONDARY OBJECTIVES:
I. Determine, preliminarily, the feasibility of administering this drug to pediatric patients with relapsed or refractory myelodysplastic syndromes.
II. Determine, preliminarily, the antitumor activity of this drug in both patient populations.
III. Determine immunologic changes in patients treated with this drug.
OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to diagnosis (solid tumor vs myelodysplastic syndromes [MDS]).
Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients with solid tumors receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Patients with MDS receive a fixed dose (do not undergo dose escalation) of lenalidomide. After completion of study treatment, patients are followed annually.
PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
California
-
Arcadia, California, Vereinigte Staaten, 91006-3776
- COG Phase I Consortium
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Diagnosis of 1 of the following:
Histologically confirmed solid tumor
- No brain tumors
Myelodysplastic syndromes (MDS)
- No refractory anemia with excess blasts in transformation or other forms of acute myeloid leukemia (AML)
- No FAB diagnosis of refractory anemia with excess blasts in transition and other forms of AML
- Newly diagnosed MDS with chromosome 5q abnormalities
- Relapsed or refractory disease including relapse after stem cell transplantation
- Measurable or evaluable disease (solid tumor patients only)
- No known curative or life-prolonging therapy exists
- No bone marrow involvement by tumor (solid tumor patients only)
- No CNS tumors
- Performance status - Karnofsky 50-100% (for patients > 10 years of age)
- Performance status - Lansky 50-100% (for patients ≤ 10 years of age)
- Absolute neutrophil count ≥ 1,000/mm^3 (for patients with solid tumors)
Platelet count ≥ 100,000/mm^3 (30,000 for patients with MDS)
- Only patients with MDS may receive transfusions to support platelet counts
- Hemoglobin ≥ 8.0 g/dL (transfusions allowed)
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT ≤ 110*
- Albumin ≥ 2 g/dL
- Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min
Creatinine based on age as follows:
- Creatinine ≤ 0.8 mg/dL (for patients ≤ 5 years of age)
- Creatinine ≤ 1 mg/dL (for patients 6 to 10 years of age)
- Creatinine ≤ 1.2 mg/dL (for patients 11 to 15 years of age)
- Creatinine ≤ 1.5 mg/dL (for patients over 15 years of age)
- No parent or sibling with a known history of venous thrombosis before the age of 50 OR arterial thrombosis before the age of 40
- No thromboembolic event except catheter-related thrombosis
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective double-method contraception 4 weeks before, during, and for ≥ 4 weeks after completion of study treatment
- Body surface area ≥ 0.4m^2
- No uncontrolled infection
- No active graft-vs-host disease from prior stem cell transplant or rescue
- Recovered from prior immunotherapy
- At least 1 week since prior biologic agents
- At least 1 week since prior hematologic growth factors (2 weeks for pegfilgrastim)
- At least 3 months since prior stem cell transplant or rescue (without total body irradiation [TBI])
- Prior thalidomide allowed
- No other concurrent immunotherapy
- No other concurrent biologic therapy
- More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered
- No concurrent chemotherapy
- Concurrent dexamethasone allowed provided the dose has been either decreasing or stable for the past 7 days
- See Biologic therapy
- Recovered from prior radiotherapy
- At least 2 weeks since prior local palliative (small port) radiotherapy
- At least 6 months since prior TBI, craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis
- At least 6 weeks since other prior substantial bone marrow radiotherapy
- No concurrent radiotherapy
- No other concurrent investigational drugs or agents
- No other concurrent anticancer agents
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment (lenalidomide)
Patients receive oral lenalidomide once daily on days 1-21.
Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
|
Mündlich gegeben
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Maximum tolerated dose of lenolidomide defined as the maximum dose at which fewer than one-third of patients experience DLT
Zeitfenster: 28 days
|
Graded using the CTCAE version 3.0.
|
28 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Overall response assessed using RECIST criteria
Zeitfenster: Up to 30 days after completion of study treatment
|
A patient will be considered to have responded if she or he demonstrates either a bone marrow or cytogenetic response.
Each patient will be classified according to the maximum response of the two criteria, where the classification from maximum to minimum will be: CR, PR or nonresponse.
|
Up to 30 days after completion of study treatment
|
Adverse events defined using the NCI CTCAE version 3.0
Zeitfenster: Up to 30 days after completion of study treatment
|
Up to 30 days after completion of study treatment
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Stacey Berg, COG Phase I Consortium
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen
- Erkrankung
- Erkrankungen des Knochenmarks
- Hämatologische Erkrankungen
- Krebsvorstufen
- Syndrom
- Myelodysplastische Syndrome
- Präleukämie
- Anämie
- Anämie, refraktär, mit Exzess von Blasten
- Anämie, refraktär
- Physiologische Wirkungen von Arzneimitteln
- Antineoplastische Mittel
- Immunologische Faktoren
- Angiogenese-Inhibitoren
- Angiogenese-modulierende Mittel
- Wuchsstoffe
- Wachstumshemmer
- Lenalidomid
Andere Studien-ID-Nummern
- NCI-2012-01820 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- U01CA097452 (US NIH Stipendium/Vertrag)
- COG-ADVL0319
- NCI-P6553
- CDR0000413700
- NCI-06-C-0052
- ADVL0319 (Andere Kennung: CTEP)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lenalidomid
-
Sidney Kimmel Comprehensive Cancer Center at Johns...BeendetMyelodysplastisches SyndromVereinigte Staaten
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncAbgeschlossenDiffuses großzelliges B-Zell-LymphomSpanien
-
Celgene CorporationICON Clinical ResearchAbgeschlossenMyelodysplastische SyndromeDeutschland, Israel, Vereinigtes Königreich, Spanien, Belgien, Italien, Frankreich, Niederlande, Schweden
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; China Medical University Hospital; Chang... und andere MitarbeiterNoch keine RekrutierungPeriphere T-Zell-Lymphome (PTCL)Taiwan
-
Groupe Francophone des MyelodysplasiesUnbekanntMyelodysplastische SyndromeFrankreich
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA Medical... und andere MitarbeiterAbgeschlossen
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.AbgeschlossenMultiples MyelomFrankreich
-
Universitätsklinikum Hamburg-EppendorfAbgeschlossenMultiples MyelomDeutschland
-
Samsung Medical CenterRekrutierungRezidiviertes und/oder refraktäres Non-Hodgkin-T-Zell-LymphomKorea, Republik von